Feasibility and Acceptability of HIV Prevention Medication PrEP in a Family Planning Clinic

What this Trial Is About

This research aims to understand patient and physician perspectives on offering medications known as pre-exposure prophylaxis PrEP to prevent HIV transmission in a family planning clinic. The study focuses on whether patients find it acceptable to be asked about and offered PrEP during their visits, and explores the factors that make it easier or harder to discuss and begin PrEP in this clinical setting. The study is a pilot designed to gather data on feasibility and acceptability to help expand PrEP services in such clinics. Participants include patients who will receive standardized counseling about PrEP and have the option to start PrEP as part of their usual care. Physicians will receive standardized training on PrEP screening and initiation protocols and will support patients interested in starting PrEP. Both patients and physicians will complete surveys about their experiences, and a subgroup of physicians may also participate in in-depth interviews. The study does not include a control group and integrates into routine family planning care. Participants will be approached by a research assistant for consent and receive a 25 gift card after completing a post-intervention survey. Physicians complete pre- and post-study surveys and possibly interviews. The study measures acceptability, feasibility, and appropriateness of the intervention up to 6 hours for patients and up to 12 months for physicians. The study runs from May 2026 to December 2026, focusing on integrating PrEP screening and initiation into clinical workflow and understanding barriers and facilitators from both patients and providers.

Bringing Medicines for HIV Prevention to a Family Planning Clinic